Physician profile
Devinder Singh
NPI 1770580037
$3,999.56
in general payments reported to CMS, 2019-2025
46 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,338 · 2020: $250 · 2021: $131 · 2022: $629 · 2023: $266 · 2024: $95.04 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.55 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $541.34 | 2019-2025 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $296.88 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $195.82 | 2019-2020 | |
| Janssen Biotech, INC. | $182.35 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $177.44 | 2019-2024 | |
| Abbvie INC. | $172.62 | 2019-2024 | Venclexta |
| Lilly USA, LLC | $163.53 | 2019-2022 | |
| Pfizer INC. | $162.93 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $145.91 | 2019-2023 | Keytruda |
| Janssen Scientific Affairs, LLC | $141.06 | 2022 | |
| Tesaro, INC. | $137.44 | 2019 | |
| Edwards Lifesciences Corporation | $122.49 | 2022 | |
| Advanced Accelerator Applications | $120.24 | 2019 | |
| Sun Pharmaceutical Industries INC. | $111.22 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.